Locations:
Search
Stanley Hazen, MD, PhD, founder of Zehna Therapeutics, a Cleveland Clinic Innovations portfolio company has been focusing on the relationship between heart and metabolic health for much of his 25 years at Cleveland Clinic. Inhibitors that target gut microbial enzymes are likely the key to treating a variety of cardiovascular diseases, some of which have no other cure.
Health system venture fund leaders discussed their investment strategy, how it changed during the pandemic, and their plans for the post-PHE era.
The Proof of Concept Office is pleased to announce the new class of Innovation Fellows.
An innovative new treatment for T-cell lymphoma (TCL) is one step closer to reaching clinical trials.
Proceeds will enable the initiation of the pivotal clinical trial RESTORE.
Cleveland Clinic Innovations prides itself on fostering new ways to advance patient care.
Results lay the groundwork for new methods of identifying high risk epilepsy patients
